Table 2.
Clinicopathological parameters in 35 patients with unresectable hepatocellular carcinoma who received lenvatinib.
| Characteristics | Liver Transplantation Group # (n = 10) | Control Group (n = 25) | p Value |
|---|---|---|---|
| Age | |||
| <60 years | 8 (80.0%) | 11 (44.0%) | 0.05 |
| ≥60 years | 2 (20.0%) | 14 (56.0%) | |
| ECOG performance status | |||
| 0 | 3 (30.0%) | 4 (16.0%) | 0.35 |
| 1 | 7 (70.0%) | 21 (84.0%) | |
| Sex | |||
| Male | 9 (90.0%) | 22 (88.0%) | 0.87 |
| Female | 1 (10.0%) | 3 (12.0%) | |
| Child–Pugh classification | |||
| A | 10 (100.0%) | 25 (100.0%) | 1.0 |
| BCLC staging classification | |||
| B | 2 (20.0%) | 1 (4.0%) | 0.13 |
| C | 8 (80.0%) | 24 (96.0%) | |
| Hepatitis B | |||
| Yes | 6 (60.0%) | 17 (68.0%) | 0.65 |
| No | 4 (40.0%) | 8 (32.0%) | |
| Hepatitis C | |||
| Yes | 4 (40.0%) | 2 (8.0%) | 0.023 * |
| No | 6 (60.0%) | 23 (92.0%) | |
| Macrovascular invasion (including main PVT) at the time of lenvatinib | |||
| Yes | 0 (0%) | 9 (36.0%) | 0.042 * |
| No | 10 (100.0%) | 16 (64.0%) | |
| Hepatectomy before lenvatinib treatment | |||
| Yes | 10 (100.0%) | 15 (60.0%) | 0.018 * |
| No | 0 (0%) | 10 (40.0%) | |
| Extrahepatic spread at the time of lenvatinib | |||
| Yes | 9 (90.0%) | 20 (80.0%) | 0.48 |
| No | 1 (10.0%) | 5 (20.0%) | |
| AFP level > 400 at the time of lenvatinib | |||
| Yes | 2 (20.0%) | 13 (52.0%) | 0.08 |
| No | 8 (80.0%) | 12 (48.0%) |
ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer; PVT: portal vein thrombosis. # Lenvatinib used for tumor recurrence after liver transplantation * Statistically significant.